Ruvembri

Japanese patent granted for technology that inhibits TCTP released from dead tumor cells using antibodies to suppress the accumulation of MDSCs in the tumor microenvironment 日本授予专利：利用抗体抑制死亡肿瘤细胞释放的TCTP，从而抑制肿瘤微环境中MDSCs的积累Granted claims are not expressly limited to specific antibody CDRs or amino acid sequences, but are defined by function and therapeutic use 授权权利要求并未明确限于特定的抗体互补决定区（CDR）或氨基酸序列，而是由功能和治疗用途来界定。Patent claims cover inhibition of PMN-MDSC accumulation as well as cancer therapeutics and therapeutic compositions containing the inhibitor 专利权利要求涵盖对多形核髓源性抑制细胞（PMN-MDSC）积累的抑制，以及含有该抑制剂的癌症治疗药物和治疗组合物。Strengthens the core intellectual property portfolio supporting the development of BIO101 and the global commercialization of TCTP-targeting antibodies 加强支持BIO101开发及TCTP靶向抗体全球商业化的核心知识产权组合SEOUL, South Korea 韩国首尔, ，July 13, 2026 2026年7月13日/PRNewswire/ -- Boostimmune announced on July 13, 2026 that it has secured a Japanese patent covering technology that uses antibodies to inhibit the function of translationally controlled tumor protein (TCTP) released from dead tumor cells, thereby suppressing the accumulation of myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment.. /PRNewswire/ -- Boostimmune 于2026年7月13日宣布，已获得一项日本专利，该专利涵盖利用抗体抑制由死亡肿瘤细胞释放的翻译控制肿瘤蛋白（TCTP）功能的技术，从而抑制肿瘤微环境中髓源性抑制细胞（MDSCs）的积聚。The granted claims are not expressly limited to the individual complementarity-determining regions (CDRs) or amino acid sequences of a specific antibody. Instead, they functionally define an anti-TCTP antibody that inhibits the activity of TCTP released from dead tumor cells and suppresses MDSC accumulation in the tumor microenvironment. 授权权利要求并未明确限定于特定抗体的个别互补决定区（CDR）或氨基酸序列。相反，它们在功能上定义了一种抗TCTP抗体，该抗体能够抑制从死亡肿瘤细胞释放的TCTP的活性，并抑制肿瘤微环境中髓源性抑制细胞（MDSC）的积聚。The claims also cover inhibition of polymorphonuclear MDSC (PMN-MDSC) accumulation and cancer therapeutics or therapeutic compositions containing the inhibitor as an active ingredient.. 这些权利要求还涵盖抑制多形核髓源性抑制细胞（PMN-MDSC）的积累，以及含有该抑制剂作为活性成分的癌症治疗药物或治疗组合物。Through this patent, Boostimmune has strengthened its intellectual property position in Japan not only for its proprietary BIO101 antibody candidate, but also for the development of therapeutics that modulate the immunosuppressive tumor microenvironment through the claimed TCTP-targeting mechanism. 凭借此项专利，Boostimmune不仅为其专有抗体候选药物BIO101，也为通过所主张的TCTP靶向机制调节免疫抑制性肿瘤微环境的治疗药物开发，加强了其在日本的知识产权地位。BIO101 is a novel immuno-oncology program designed to regulate MDSCs, one of the major immunosuppressive cell populations in the tumor microenvironment. BIO101 是一种新型肿瘤免疫治疗项目，旨在调节髓源性抑制细胞（MDSCs），这是肿瘤微环境中主要的免疫抑制细胞群之一。Although TCTP has primarily been known for its intracellular functions, it can be released into the extracellular space during tumor cell death. Extracellular TCTP may act on immunosuppressive myeloid cells, promote the recruitment and accumulation of MDSCs within tumors, and contribute to the suppression of antitumor immune responses.. 尽管TCTP主要以其细胞内功能而闻名，但在肿瘤细胞死亡过程中，它可被释放到细胞外空间。细胞外的TCTP可能作用于免疫抑制性髓系细胞，促进髓源性抑制细胞（MDSCs）在肿瘤内的募集和积累，从而有助于抑制抗肿瘤免疫反应。Boostimmune is developing a therapeutic strategy that blocks extracellular TCTP with an antibody, with the aim of reducing MDSC accumulation in tumors and restoring antitumor immune activity. Boostimmune 正在开发一种通过抗体阻断细胞外 TCTP 的治疗策略，旨在减少肿瘤中髓源性抑制细胞（MDSC）的积聚，并恢复抗肿瘤免疫活性。The company believes that the newly granted patent may represent an important intellectual property right to consider in connection with the clinical development, licensing, and commercialization in Japan of TCTP-targeting antibody therapeutics based on the same or a similar mechanism of action. 该公司认为，新授予的专利可能构成一项重要的知识产权，在基于相同或类似作用机制的TCTP靶向抗体疗法在日本的临床开发、许可及商业化过程中需予以考虑。BIO101 originated from research conducted by the laboratory of Tadatsugu Taniguchi, Professor Emeritus at the University of Tokyo and a globally recognized immunologist. The program was subsequently in-licensed by Boostimmune. BIO101源自东京大学名誉教授、国际知名免疫学家谷口忠嗣教授实验室开展的研究。随后，Boostimmune获得了该项目的授权许可。Professor Taniguchi's research team demonstrated that extracellular TCTP released from tumor cells can act on immunosuppressive myeloid cells and promote the accumulation of MDSCs within tumors. The findings were published in 谷口教授的研究团队证实，肿瘤细胞释放的胞外TCTP可作用于免疫抑制性髓系细胞，并促进MDSC在肿瘤内的积聚。相关研究成果发表于Nature Immunology 《自然·免疫学》in 2021. Professor Taniguchi is also a co-founder of Boostimmune. 2021年。谷口教授也是Boostimmune的联合创始人。Building on this research, Boostimmune has identified antibodies that block TCTP function and has advanced candidate optimization and preclinical development based on antibody binding properties, inhibition of MDSC accumulation, and activation of antitumor immune responses. 在此基础上，Boostimmune 已鉴定出能够阻断 TCTP 功能的抗体，并基于抗体结合特性、对髓源性抑制细胞（MDSC）积累的抑制作用以及抗肿瘤免疫反应的激活，推进了候选抗体的优化和临床前开发。'This Japanese patent is significant because it is not limited to the sequence of a single BIO101 antibody,' said Gwanghee Lee, Ph.D., Chief Executive Officer of Boostimmune. 'Rather, the granted claims are centered on the function of inhibiting TCTP released from dead tumor cells to suppress MDSC accumulation in tumors, as well as the related therapeutic uses and compositions.'. Boostimmune 首席执行官李光熙博士表示：“这项日本专利意义重大，因为它并不局限于单一 BIO101 抗体的序列。相反，获授权的权利要求核心在于抑制由死亡肿瘤细胞释放的 TCTP，从而抑制肿瘤中髓源性抑制细胞（MDSC）的蓄积，以及相关的治疗用途和组合物。”He added, 'Because this patent may be relevant to the development and commercialization of therapeutics that use TCTP antibodies to regulate the immunosuppressive tumor microenvironment through the same or a similar mechanism, we intend to accelerate the development of BIO101 while actively pursuing strategic collaborations with global pharmaceutical and biotechnology companies.'. 他补充道：“由于该专利可能与使用TCTP抗体通过相同或类似机制调节免疫抑制性肿瘤微环境的治疗药物的开发和商业化相关，我们打算在积极与全球制药和生物技术公司寻求战略合作的同时，加速BIO101的开发。”Boostimmune is an oncology-focused biotechnology company co-founded in 2021 by Gwanghee Lee and Professor Tadatsugu Taniguchi. The company is developing multiple biologics-based oncology programs, including BIO101, an immuno-oncology program targeting TCTP, as well as novel antibody-drug conjugate programs.. Boostimmune 是一家专注于肿瘤学的生物技术公司，由 Gwanghee Lee 和 Tadatsugu Taniguchi 教授于 2021 年联合创立。该公司正在开发多种基于生物制剂的肿瘤学项目，包括靶向 TCTP 的免疫肿瘤学项目 BIO101，以及新型抗体药物偶联物（ADC）项目。CONTACT: 联系方式：[emailprotected] [emailprotected]SOURCE Boostimmune 来源：Boostimmune21 二十一% %more press release views with 更多新闻稿浏览量，通过Request a Demo 申请演示

Japanese patent granted for technology that inhibits TCTP released from dead tumor cells using antibodies to suppress the accumulation of MDSCs in the tumor microenvironment Granted claims are not expressly limited to specific antibody CDRs or amino acid sequences, but are defined by function and therapeutic use Patent claims cover inhibition of PMN-MDSC accumulation as well as cancer therapeutics and therapeutic compositions containing the inhibitor Strengthens the core intellectual property portfolio supporting the development of BIO101 and the global commercialization of TCTP-targeting antibodies SEOUL, South Korea, July 13, 2026 /PRNewswire/ -- Boostimmune announced on July 13, 2026 that it has secured a Japanese patent covering technology that uses antibodies to inhibit the function of translationally controlled tumor protein (TCTP) released from dead tumor cells, thereby suppressing the accumulation of myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment. The granted claims are not expressly limited to the individual complementarity-determining regions (CDRs) or amino acid sequences of a specific antibody. Instead, they functionally define an anti-TCTP antibody that inhibits the activity of TCTP released from dead tumor cells and suppresses MDSC accumulation in the tumor microenvironment. The claims also cover inhibition of polymorphonuclear MDSC (PMN-MDSC) accumulation and cancer therapeutics or therapeutic compositions containing the inhibitor as an active ingredient. Through this patent, Boostimmune has strengthened its intellectual property position in Japan not only for its proprietary BIO101 antibody candidate, but also for the development of therapeutics that modulate the immunosuppressive tumor microenvironment through the claimed TCTP-targeting mechanism. BIO101 is a novel immuno-oncology program designed to regulate MDSCs, one of the major immunosuppressive cell populations in the tumor microenvironment. Although TCTP has primarily been known for its intracellular functions, it can be released into the extracellular space during tumor cell death. Extracellular TCTP may act on immunosuppressive myeloid cells, promote the recruitment and accumulation of MDSCs within tumors, and contribute to the suppression of antitumor immune responses. Boostimmune is developing a therapeutic strategy that blocks extracellular TCTP with an antibody, with the aim of reducing MDSC accumulation in tumors and restoring antitumor immune activity. The company believes that the newly granted patent may represent an important intellectual property right to consider in connection with the clinical development, licensing, and commercialization in Japan of TCTP-targeting antibody therapeutics based on the same or a similar mechanism of action. BIO101 originated from research conducted by the laboratory of Tadatsugu Taniguchi, Professor Emeritus at the University of Tokyo and a globally recognized immunologist. The program was subsequently in-licensed by Boostimmune. Professor Taniguchi's research team demonstrated that extracellular TCTP released from tumor cells can act on immunosuppressive myeloid cells and promote the accumulation of MDSCs within tumors. The findings were published in Nature Immunology in 2021. Professor Taniguchi is also a co-founder of Boostimmune. Building on this research, Boostimmune has identified antibodies that block TCTP function and has advanced candidate optimization and preclinical development based on antibody binding properties, inhibition of MDSC accumulation, and activation of antitumor immune responses. "This Japanese patent is significant because it is not limited to the sequence of a single BIO101 antibody," said Gwanghee Lee, Ph.D., Chief Executive Officer of Boostimmune. "Rather, the granted claims are centered on the function of inhibiting TCTP released from dead tumor cells to suppress MDSC accumulation in tumors, as well as the related therapeutic uses and compositions." He added, "Because this patent may be relevant to the development and commercialization of therapeutics that use TCTP antibodies to regulate the immunosuppressive tumor microenvironment through the same or a similar mechanism, we intend to accelerate the development of BIO101 while actively pursuing strategic collaborations with global pharmaceutical and biotechnology companies." Boostimmune is an oncology-focused biotechnology company co-founded in 2021 by Gwanghee Lee and Professor Tadatsugu Taniguchi. The company is developing multiple biologics-based oncology programs, including BIO101, an immuno-oncology program targeting TCTP, as well as novel antibody-drug conjugate programs. CONTACT: [email protected] SOURCE Boostimmune 21% more press release views with Request a Demo